Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12906) 12906
Book Chapter (60) 60
Conference Proceeding (36) 36
Dissertation (33) 33
Publication (18) 18
Government Document (7) 7
Newsletter (7) 7
Book / eBook (6) 6
Web Resource (5) 5
Magazine Article (4) 4
Newspaper Article (2) 2
Streaming Video (2) 2
Book Review (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10068) 10068
science & technology (9177) 9177
camptothecin - analogs & derivatives (8532) 8532
life sciences & biomedicine (8481) 8481
camptothecin - administration & dosage (5024) 5024
oncology (4826) 4826
female (4722) 4722
male (4413) 4413
camptothecin - pharmacology (3706) 3706
biological and medical sciences (3664) 3664
antineoplastic combined chemotherapy protocols - therapeutic use (3641) 3641
middle aged (3504) 3504
medical sciences (3359) 3359
aged (3283) 3283
animals (3086) 3086
adult (2695) 2695
irinotecan (2660) 2660
chemotherapy (2634) 2634
camptothecin (2597) 2597
antineoplastic agents (2446) 2446
camptothecin - therapeutic use (2402) 2402
pharmacology. drug treatments (2396) 2396
colorectal neoplasms - drug therapy (2181) 2181
pharmacology & pharmacy (2040) 2040
cancer (1978) 1978
treatment outcome (1868) 1868
fluorouracil - administration & dosage (1805) 1805
tumors (1790) 1790
camptothecin - adverse effects (1784) 1784
mice (1703) 1703
cell line, tumor (1502) 1502
colorectal neoplasms - pathology (1412) 1412
colorectal cancer (1390) 1390
antineoplastic combined chemotherapy protocols - adverse effects (1350) 1350
leucovorin - administration & dosage (1239) 1239
camptothecin - pharmacokinetics (1184) 1184
topoisomerase i inhibitors (1156) 1156
organoplatinum compounds - administration & dosage (1151) 1151
biochemistry & molecular biology (1142) 1142
antineoplastic agents - pharmacology (1128) 1128
antineoplastic agents, phytogenic - pharmacology (1088) 1088
antineoplastic agents, phytogenic - administration & dosage (1080) 1080
antineoplastic combined chemotherapy protocols - administration & dosage (1074) 1074
camptothecin - chemistry (1072) 1072
drug administration schedule (1068) 1068
apoptosis (1008) 1008
dose-response relationship, drug (1007) 1007
apoptosis - drug effects (953) 953
antineoplastic agents - therapeutic use (928) 928
antineoplastic agents, phytogenic - therapeutic use (923) 923
physical sciences (910) 910
chemistry (908) 908
lung neoplasms - drug therapy (867) 867
aged, 80 and over (846) 846
analysis (819) 819
disease-free survival (816) 816
research (800) 800
cisplatin - administration & dosage (798) 798
care and treatment (793) 793
neoplasms - drug therapy (778) 778
tumor cells, cultured (775) 775
adenocarcinoma - drug therapy (774) 774
survival rate (765) 765
dna damage (758) 758
fluorouracil - therapeutic use (758) 758
gastroenterology. liver. pancreas. abdomen (749) 749
deoxycytidine - analogs & derivatives (734) 734
liver neoplasms - secondary (727) 727
neoplasm staging (720) 720
dna topoisomerases, type i - metabolism (715) 715
antineoplastic agents - administration & dosage (711) 711
metastasis (689) 689
neoplasm metastasis (687) 687
bevacizumab (678) 678
medicine & public health (672) 672
cell biology (661) 661
stomach. duodenum. small intestine. colon. rectum. anus (658) 658
cell survival - drug effects (657) 657
enzyme inhibitors - pharmacology (643) 643
retrospective studies (627) 627
liver neoplasms - drug therapy (610) 610
survival analysis (591) 591
mice, nude (581) 581
antimitotic agents (567) 567
antineoplastic agents, phytogenic - pharmacokinetics (567) 567
time factors (564) 564
drug resistance, neoplasm (560) 560
general aspects (558) 558
antineoplastic agents, phytogenic - adverse effects (551) 551
drug delivery systems (539) 539
drug therapy (539) 539
antibodies, monoclonal, humanized (538) 538
prognosis (537) 537
fluorouracil - adverse effects (529) 529
rats (526) 526
camptothecin - metabolism (524) 524
combined modality therapy (523) 523
deoxycytidine - administration & dosage (520) 520
camptothecin - toxicity (511) 511
drugs (509) 509
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12279) 12279
Japanese (859) 859
Chinese (228) 228
French (95) 95
German (63) 63
Russian (37) 37
Italian (33) 33
Hungarian (14) 14
Portuguese (14) 14
Spanish (13) 13
Korean (12) 12
Czech (4) 4
Dutch (3) 3
Lithuanian (3) 3
Polish (3) 3
Danish (2) 2
Croatian (1) 1
Norwegian (1) 1
Romanian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
by Alberto F. Sobrero and Joan Maurel and Louis Fehrenbacher and Werner Scheithauer and Yousif A. Abubakr and Manfred P. Lutz and M. Eugenia Vega-Villegas and Cathy Eng and Ernst U. Steinhauer and Jana Prausova and Heinz-Josef Lenz and Christophe Borg and Gary Middleton and Hendrik Kröning and Gabriele Luppi and Oliver Kisker and Angela Zubel and Christiane Langer and Justin Kopit and Howard A. Burris III
Journal of clinical oncology, ISSN 0732-183X, 05/2008, Volume 26, Issue 14, pp. 2311 - 2319
Life Sciences & Biomedicine | Oncology | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | Medical sciences | Tumors | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antibodies, Monoclonal, Humanized | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Cetuximab | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Receptor, Epidermal Growth Factor - biosynthesis | Camptothecin - therapeutic use | Pyrimidines - administration & dosage | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Quality of Life | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - adverse effects | Index Medicus | Camptothecin | Organoplatinum Compounds | Antineoplastic Combined Chemotherapy Protocols | Antibodies, Monoclonal | Life Sciences | Pyrimidines | Immunology | Colorectal Neoplasms | Receptor, Epidermal Growth Factor
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
by Loupakis, Fotios and Cremolini, Chiara and Masi, Gianluca and Lonardi, Sara and Zagonel, Vittorina and Salvatore, Lisa and Cortesi, Enrico and Tomasello, Gianluca and Ronzoni, Monica and Spadi, Rosella and Zaniboni, Alberto and Tonini, Giuseppe and Buonadonna, Angela and Amoroso, Domenico and Chiara, Silvana and Carlomagno, Chiara and Boni, Luca and Boni, Corrado and Allegrini, Giacomo and Falcone, Alfredo
The New England journal of medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 17, pp. 1609 - 1618
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | General aspects | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Immunomodulators | Tumors | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Adult | Female | Leucovorin - therapeutic use | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Treatment outcome | Care and treatment | Analysis | Colorectal cancer | Dosage and administration | Leucovorin | Fluorouracil | Colorectal carcinoma | Diarrhea | Metastasis | Survival | Patients | Clinical outcomes | Metastases | Irinotecan | Stomatitis | Chemotherapy | Neurotoxicity | Oxaliplatin | Monoclonal antibodies | Vascular endothelial growth factor | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Enzyme-activatable polymer-drug conjugate augments tumour penetration and treatment efficacy
by Zhou, Quan and Shao, Shiqun and Wang, Jinqiang and Xu, Changhuo and Xiang, Jiajia and Piao, Ying and Zhou, Zhuxian and Yu, Qingsong and Tang, Jianbin and Liu, Xiangrui and Gan, Zhihua and Mo, Ran and Gu, Zhen and Shen, Youqing
Nature nanotechnology, ISSN 1748-3387, 08/2019, Volume 14, Issue 8, pp. 799 - 809
Science & Technology - Other Topics | Materials Science | Nanoscience & Nanotechnology | Technology | Materials Science, Multidisciplinary | Science & Technology | Camptothecin - pharmacokinetics | Neoplasms - metabolism | Camptothecin - metabolism | Drug Carriers - metabolism | Camptothecin - therapeutic use | Humans | gamma-Glutamyltransferase - metabolism | Mice, Inbred ICR | Drug Delivery Systems | Neoplasms - drug therapy | Antineoplastic Agents, Phytogenic - administration & dosage | Animals | Cell Line, Tumor | Camptothecin - administration & dosage | Female | Antineoplastic Agents, Phytogenic - metabolism | Mice | Mice, Inbred BALB C | Transcytosis | Antineoplastic Agents, Phytogenic - therapeutic use | Antineoplastic Agents, Phytogenic - pharmacokinetics | Polymers - metabolism | Camptothecin | Conjugates | Animal models | Drug delivery systems | Amines | Gemcitabine | g-Glutamyltransferase | Caveolae | Blood vessels | Drug delivery | Cell membranes | Endothelial cells | Anticancer properties | Endocytosis | Penetration | Diffusion barriers | Solid tumors | Polymers | Pancreas | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text A triple threat for cancer treatment
by James Ankrum
Science translational medicine, ISSN 1946-6234, 12/2020, Volume 12, Issue 572
Camptothecin | Chemotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Transformative Nanomedicine of an Amphiphilic Camptothecin Prodrug for Long Circulation and High Tumor Uptake in Cancer Therapy
by Zhang, Fuwu and Zhu, Guizhi and Jacobson, Orit and Liu, Yi and Chen, Kai and Yu, Guocan and Ni, Qianqian and Fan, Jing and Yang, Zhen and Xu, Frederick and Fu, Xiao and Wang, Zhe and Ma, Ying and Niu, Gang and Zhao, Xiaobin and Chen, Xiaoyuan
ACS nano, ISSN 1936-0851, 09/2017, Volume 11, Issue 9, pp. 8838 - 8848
self-assembly | camptothecin prodrug | drug delivery | nanostructures | albumin | Physical Sciences | Chemistry | Materials Science | Nanoscience & Nanotechnology | Technology | Materials Science, Multidisciplinary | Science & Technology - Other Topics | Chemistry, Multidisciplinary | Chemistry, Physical | Science & Technology | Prodrugs - administration & dosage | Camptothecin - chemistry | Nanoparticles - chemistry | Humans | Surface-Active Agents - pharmacokinetics | Prodrugs - chemistry | Drug Delivery Systems | Antineoplastic Agents, Phytogenic - administration & dosage | Camptothecin - blood | Camptothecin - administration & dosage | Female | Antineoplastic Agents, Phytogenic - pharmacokinetics | Antineoplastic Agents, Phytogenic - blood | Camptothecin - pharmacokinetics | Oxidation-Reduction | HCT116 Cells | Solubility | Antineoplastic Agents, Phytogenic - chemistry | Nanoconjugates - administration & dosage | Neoplasms - drug therapy | Animals | Prodrugs - pharmacokinetics | Mice, Nude | Mice | Surface-Active Agents - chemistry | Nanoconjugates - chemistry | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer
by Liu, Xiangsheng and Situ, Allen and Kang, Yanan and Villabroza, Katie Rose and Liao, Yupei and Chang, Chong Hyun and Donahue, Timothy and Nel, Andre E and Meng, Huan
ACS nano, ISSN 1936-0851, 02/2016, Volume 10, Issue 2, pp. 2702 - 2715
FOLFIRINOX | pancreatic cancer | toxicity reduction | irinotecan | mesoporous silica nanoparticle | proton gradient | lipid bilayer | Camptothecin - pharmacokinetics | Camptothecin - adverse effects | Nanoparticles - chemistry | Silicon Dioxide - chemistry | Nanoparticles - adverse effects | Adenocarcinoma - drug therapy | Liposomes - adverse effects | Pancreatic Neoplasms - drug therapy | Antineoplastic Agents, Phytogenic - administration & dosage | Liposomes - chemistry | Animals | Cell Line, Tumor | Drug Liberation | Camptothecin - administration & dosage | Female | Mice | Lipid Bilayers - chemistry | Antineoplastic Agents, Phytogenic - pharmacokinetics | Antineoplastic Agents, Phytogenic - adverse effects | Camptothecin - analogs & derivatives | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
by Weiss, Glen J and Chao, Joseph and Neidhart, Jeffrey D and Ramanathan, Ramesh K and Bassett, Dawn and Neidhart, James A and Choi, Chung Hang J and Chow, Warren and Chung, Vincent and Forman, Stephen J and Garmey, Edward and Hwang, Jungyeon and Kalinoski, D Lynn and Koczywas, Marianna and Longmate, Jeffrey and Melton, Roger J and Morgan, Robert and Oliver, Jamie and Peterkin, Joanna J and Ryan, John L and Schluep, Thomas and Synold, Timothy W and Twardowski, Przemyslaw and Davis, Mark E and Yen, Yun
Investigational new drugs, ISSN 0167-6997, 8/2013, Volume 31, Issue 4, pp. 986 - 1000
Phase 1/2a | Solid tumor | Medicine & Public Health | Nanopharmaceutical | Oncology | Polymer conjugate camptothecin | Pharmacology/Toxicology | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | General aspects | Pharmacology. Drug treatments | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Antineoplastic agents | Tumors | Cellulose - blood | Immunohistochemistry | Cyclodextrins - adverse effects | Demography | Cellulose - therapeutic use | Area Under Curve | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Nanoparticles - adverse effects | Cyclodextrins - therapeutic use | Dose-Response Relationship, Drug | Nanoparticles - therapeutic use | Camptothecin - blood | Cellulose - pharmacokinetics | Adult | Female | Cellulose - adverse effects | Camptothecin - pharmacokinetics | Camptothecin - adverse effects | Camptothecin - therapeutic use | Cyclodextrins - pharmacokinetics | Treatment Outcome | Neoplasms - diagnostic imaging | Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Cyclodextrins - blood | Biopsy | Aged | Neoplasm Staging | Neoplasms - pathology | Camptothecin | Complications and side effects | Dosage and administration | Drug therapy | Studies | Research | Cancer therapies | Pharmaceutical sciences | Index Medicus | Phase 1 | 2a
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics
by Ocean, Allyson J and Starodub, Alexander N and Bardia, Aditya and Vahdat, Linda T and Isakoff, Steven J and Guarino, Michael and Messersmith, Wells A and Picozzi, Vincent J and Mayer, Ingrid A and Wegener, William A and Maliakal, Pius and Govindan, Serengulam V and Sharkey, Robert M and Goldenberg, David M
Cancer, ISSN 0008-543X, 10/2017, Volume 123, Issue 19, pp. 3843 - 3854
clinical trial | trophoblastic cell‐surface antigen (Trop‐2) | epithelial cancers | antibody‐drug conjugate | IMMU‐132 (sacituzumab govitecan) | SN‐38 | trophoblastic cell-surface antigen (Trop-2) | SN-38 | antibody-drug conjugate | IMMU-132 (sacituzumab govitecan) | Life Sciences & Biomedicine | Oncology | Science & Technology | Neoplasms - metabolism | Humans | Middle Aged | Half-Life | Immunoconjugates - pharmacokinetics | Male | Response Evaluation Criteria in Solid Tumors | Immunoconjugates - administration & dosage | Glucuronosyltransferase - genetics | Antineoplastic Agents, Phytogenic - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Antibodies, Monoclonal, Humanized - pharmacokinetics | Camptothecin - blood | Aged, 80 and over | Antigens, Neoplasm - metabolism | Adult | Camptothecin - administration & dosage | Female | Neutropenia - chemically induced | Antineoplastic Agents, Phytogenic - pharmacokinetics | Antineoplastic Agents, Phytogenic - adverse effects | Camptothecin - analogs & derivatives | Immunoconjugates - adverse effects | Camptothecin - pharmacokinetics | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Cell Adhesion Molecules - metabolism | Neoplasms - drug therapy | Irinotecan | Aged | Immunoglobulin G - metabolism | Usage | Care and treatment | Safety and security measures | Analysis | Epithelial tumors | Pharmacokinetics | Antibody-drug conjugates | Camptothecin | Antigens | Toxicity | Immunoglobulin G | Breast cancer | Pharmacology | Metastasis | Criteria | Patients | Cell surface | Metastases | Uridine | Safety | Solid tumors | Drug dosages | Cancer | Tumors | Half life | Neutropenia | Glucuronosyltransferase | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment
by Wang, Jinqiang and Mao, Weiwei and Lock, Lye Lin and Tang, Jianbin and Sui, Meihua and Sun, Weilin and Cui, Honggang and Xu, Dong and Shen, Youqing
ACS nano, ISSN 1936-0851, 07/2015, Volume 9, Issue 7, pp. 7195 - 7206
polymeric micelle | 7-ethyl-10-hydroxylcamptothecin | cancer drug delivery | tumor penetration | size effect | Physical Sciences | Chemistry | Materials Science | Nanoscience & Nanotechnology | Technology | Materials Science, Multidisciplinary | Science & Technology - Other Topics | Chemistry, Multidisciplinary | Chemistry, Physical | Science & Technology | Camptothecin - pharmacokinetics | Camptothecin - therapeutic use | Humans | Mice, Inbred ICR | Antineoplastic Agents, Phytogenic - administration & dosage | Animals | Mice, Nude | Micelles | Cell Line, Tumor | Camptothecin - administration & dosage | Female | Mice | Mice, Inbred BALB C | Antineoplastic Agents, Phytogenic - therapeutic use | Antineoplastic Agents, Phytogenic - pharmacokinetics | Camptothecin - analogs & derivatives | Mammary Neoplasms, Experimental - drug therapy | Index Medicus | Drugs | Penetration | Effectiveness | Nanostructure | Physical properties | Optimization | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Safe approaches for camptothecin delivery: Structural analogues and nanomedicines
by Botella, Pablo and Rivero-Buceta, Eva
Journal of controlled release, ISSN 0168-3659, 02/2017, Volume 247, pp. 28 - 54
Stimuli-responsive | Clinical trials | Camptothecin nanomedicines | Camptothecin analogues | Structure-activity relationship | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Camptothecin - pharmacokinetics | Topoisomerase I Inhibitors - pharmacokinetics | Camptothecin - adverse effects | Nanoparticles - chemistry | Humans | Topoisomerase I Inhibitors - administration & dosage | Models, Molecular | Antineoplastic Agents, Phytogenic - chemistry | Delayed-Action Preparations - chemistry | Clinical Trials as Topic | Antineoplastic Agents, Phytogenic - administration & dosage | Topoisomerase I Inhibitors - adverse effects | Animals | Drug Liberation | Camptothecin - administration & dosage | Antineoplastic Agents, Phytogenic - pharmacokinetics | Drug Delivery Systems - methods | Nanomedicine | Topoisomerase I Inhibitors - chemistry | Antineoplastic Agents, Phytogenic - adverse effects | Camptothecin - analogs & derivatives | Magnetic fields | Enzymes | Therapeutics | Homeopathy | Materia medica and therapeutics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights